GLPwatch
Imaging of Insulinoma by Targeting Glucagonlike Peptide-1 Receptor.
PET Clin · 2021
Last updated 2026-05-28GLP-1 receptor imaging, which uses a radioactive version of the drug exendin-4, has been shown to effectively detect insulinomas—tumors that cause low blood sugar—in patients with hyperinsulinemic hypoglycemia. This method is highly accurate for locating these tumors before surgery, according to clinical research.
AI summary of the abstract below.
| Journal | PET Clin, 2021 |
|---|---|
| Citations | 7 |
| Relative citation ratio | 0.77 |
| NIH percentile | 41 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
"Glucagonlike peptide-1 (GLP-1) receptor imaging, using radiolabeled exendin-4, was recently established for detecting insulinoma in patients with hyperinsulinemic hypoglycemia. It has proven to be a sensitive and specific method for preoperative localization of insulinoma. This review introduces the development, clinical research, and perspective of GLP-1 receptor imaging mainly in insulinoma.
Verbatim abstract via PubMed 33589387 ↗